FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

FDA Accepts Roche's sBLA for Lunsumio/Polivy in R/R LBCL

Roche announced that the US FDA has accepted its supplemental Biologics License Application (sBLA) for subcutaneous Lunsumio VELO (mosunetuzumab) in combination with Polivy (polatuzumab vedotin). This combination is for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including DLBCL, after at least one prior line of systemic therapy. The sBLA is based on the Phase III SUNMO study, which demonstrated a 59% reduction in the risk of disease progression or death (PFS) compared to R-GemOx. The median PFS for the Lunsumio/Polivy combination was 11.5 months, significantly longer than R-GemOx's 3.8 months. The FDA is expected to make a decision on approval by February 9, 2027.

• The US FDA has accepted Roche's sBLA for the subcutaneous formulation of Lunsumio VELO in combination with Polivy. This filing targets adult patients with relapsed or refractory large B-cell lymphoma, including DLBCL, who have received at least one prior systemic therapy, addressing a high unmet need in this aggressive disease setting.
• The sBLA is supported by robust data from the Phase III SUNMO study, demonstrating a 59% reduction in the risk of disease progression or death (PFS) for the Lunsumio/Polivy combination compared to R-GemOx (HR 0.41, 95% CI: 0.28–0.61; p<0.0001). This translated to a three-times longer median PFS of 11.5 months versus 3.8 months for the comparator arm.
• The Lunsumio/Polivy combination offers a potential chemotherapy-free, outpatient-ready treatment option, which could significantly improve access to care for patients, particularly those in community settings or rural areas facing logistical barriers to complex therapies. The safety profile was consistent with known individual drug profiles, with a low incidence of cytokine release syndrome events.

SUNMO Data: A New Hope for Relapsed/Refractory LBCL

The SUNMO trial represents one of the most compelling recent additions to the relapsed/refractory LBCL treatment landscape. This study evaluated mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) against R-GemOx as a comparator, demonstrating a superior overall response rate of 70% versus 40% (P<0.0001) and a complete response rate of 51% versus 24%. The progression-free survival benefit was equally striking, with a median PFS of 11.5 months compared to 3.8 months for R-GemOx (HR 0.41, P<0.0001). From a safety standpoint, the regimen demonstrated a manageable profile, with grade ≥2 cytokine release syndrome occurring in fewer than 5% of patients and tocilizumab usage similarly below the 5% threshold — a meaningful advantage for outpatient administration and tolerability planning.

Beyond SUNMO, several additional trials have generated clinically informative data across the R/R LBCL space. The EPCORE NHL-1 trial, evaluating subcutaneous epcoritamab (a CD3×CD20 bispecific antibody), reported a 59% ORR and 41% CR rate at a median follow-up of 37.1 months, with a median duration of CR of 36.1 months and the longest ongoing CR exceeding 43 months. Among patients achieving CR, median PFS reached 37.3 months and median OS was not reached. Safety was characterized by cytokine release syndrome in 51% of patients (predominantly low-grade), fatigue (25%), and pyrexia (25%), with no new signals emerging at long-term follow-up. A matching-adjusted indirect comparison (MAIC) between epcoritamab (EPCORE NHL-1) and axicabtagene ciloleucel (ZUMA-1) found no statistically significant differences in ORR (73.5% vs 74.3%), CR rate (48.7% vs 54.5%), PFS (adjusted HR 1.009, P=0.975), or OS (adjusted HR 0.826, P=0.546), suggesting comparable efficacy between these modalities in this indirect analytical framework. The Pola-ZR/G study (NCT06203652), a prospective observational study of polatuzumab vedotin combined with zanubrutinib plus rituximab or obinutuzumab in 22 R/R DLBCL patients (median age 68 years), reported a best overall response rate of 70% (77.8% for Pola-ZR; 63.6% for Pola-ZG), a CR rate of 45%, and a median PFS of 8.3 months, with median OS not yet reached; the most common grade 3–4 adverse events were infections and hematological toxicity.

A growing body of real-world and combinatorial data further contextualizes these findings. A Spanish real-world cohort study of tafasitamab plus lenalidomide (T/L) in 99 R/R DLBCL patients (ITT) reported an ORR of 51% and CR rate of 35%, with median OS of 12.2 months in the ITT population; in the 83-patient efficacy cohort, ORR improved to 61%, CR to 42%, and median OS to 21.8 months, with poor ECOG PS 2–4 (HR 2.1), double-hit lymphoma (HR 2.5), and refractory/progressing disease (HR 2.1) identified as independent adverse prognostic factors for PFS. A Korean external control arm study comparing L-MIND T/L data against an ICE regimen registry cohort demonstrated a significantly prolonged median OS of 34.1 months versus 6.4 months (HR 0.33; 95% CI, 0.20–0.53) after inverse probability of treatment weighting, with consistent advantages across PFS, TTNT, DoR, ORR, and CRR. In the novel combinatorial space, a 34-patient study of orelabrutinib, lenalidomide, and sintilimab in R/R DLBCL yielded an ORR of 58.8% and CR rate of 38.2%, with a 1-year OS of 77.8% and median PFS of 6 months; 82% of patients experienced treatment-related adverse events, with grade ≥3 TRAEs in 20.6%, most commonly neutropenia (64.7%) and thrombocytopenia (44.1%). Finally, a systematic meta-analysis (PROSPERO CRD420251071424) encompassing 2,122 patients across 30 studies addressed sequencing of CAR-T and bispecific antibodies, finding that CAR-T administered after BsAb yielded a pooled CR rate of 53.7% (95% CI 39.8–67.0) compared to 29.4% (95% CI 25.1–34.0) for BsAb after CAR-T (p=0.0008), while BsAb combinations post-CAR-T achieved a pooled CR rate of 46.4% — collectively suggesting that sequencing strategy carries meaningful prognostic implications for this patient population.

Addressing High Unmet Needs in Relapsed/Refractory LBCL

Despite significant advances in frontline chemoimmunotherapy, large B-cell lymphoma (LBCL) remains a disease with substantial unmet need, particularly in the relapsed/refractory (R/R) setting. Approximately 30–40% of patients are refractory to or relapse following standard R-CHOP, and outcomes in this population remain poor, with 5-year overall survival of only 31% for those receiving salvage regimens and 17% for those receiving non-salvage regimens in the rituximab era.

• Persistent treatment failure despite frontline therapy: Roughly 40% of patients do not benefit from R-CHOP, and a high proportion of those with advanced disease either relapse or fail to achieve remission. Despite numerous attempts to improve outcomes through R-CHOP intensification, consolidation, or maintenance strategies since 2000, no approach has demonstrated consistent superiority.

• Limited efficacy of salvage regimens in the rituximab era: Salvage chemotherapy and autologous stem cell transplantation (ASCT) are less effective in patients with prior rituximab exposure. Patients relapsing within the first year of rituximab-containing therapy, or those with primarily refractory disease, carry a particularly adverse prognosis. No standard salvage therapy has been established to date, and the optimal second-line chemotherapy regimen remains uncertain.

• Transplant eligibility barriers and transplantation-associated toxicity: Due to treatment-related toxicity, not all patients are eligible for high-dose chemotherapy with ASCT, resulting in heterogeneous treatment intensities across the population. Allogeneic transplantation is further limited by treatment-related mortality from graft-versus-host disease, preparative regimen toxicity, and poor immune recovery.

• Differential response by molecular subtype: Treatment benefit from rituximab-containing regimens has been more pronounced in the germinal center B-cell (GCB)-like subset, with the non-GCB subset remaining a persistently poor-risk population. Novel therapeutic strategies need to specifically target these high-risk and non-GCB patients.

• Toxicity and tolerability constraints in vulnerable populations: Elderly patients and those with comorbidities face restricted tolerability to intensive regimens. Patients with two or more comorbidities and those living alone are significantly less likely to receive salvage therapy, highlighting disparities in treatment access driven by clinical and social factors.

• Emerging therapy limitations: Bispecific antibodies such as epcoritamab carry immune-related toxicities including cytokine release syndrome (51%), immune effector cell-associated neurotoxicity syndrome, and elevated infection susceptibility — with Grade 3 infections reported in 24% of patients. CAR T-cell therapy, while promising, has a median OS of only 9.2 months in R/R settings, with a 12-month OS rate of 42.6%, and carries substantial economic burden (median per-patient cost ~355,165€, with CAR T-cell drug cost accounting for 97% of overall expenditure).

• Absence of validated predictive biomarkers: No biomarkers predictive of R-CHOP response have been identified and validated to date, including in the elderly population. Pharmacogenetic approaches — including SNP analysis across drug transport, metabolism, apoptosis, and DNA repair pathways — remain investigational and require prospective validation before clinical application.

Lunsumio/Polivy's Role in Evolving R/R LBCL Treatment

Over the past five years, the treatment landscape for relapsed/refractory large B-cell lymphoma (R/R LBCL) has undergone substantial transformation, driven by the regulatory approval and clinical maturation of multiple novel therapeutic modalities. CD19-directed CAR T-cell therapies have emerged as a central pillar of the relapsed/refractory setting, with pivotal data from the ZUMA-7 and TRANSFORM trials supporting the approval of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel for disease refractory to or relapsing within 12 months of first-line chemoimmunotherapy. Long-term follow-up from the ZUMA-1 trial at a median of 63.1 months confirmed durable benefit for axi-cel, with an objective response rate of 83%, a complete response rate of 58%, and an estimated 5-year overall survival of 42.6% — with no new serious adverse events identified on extended follow-up. Notably, polyclonal B-cell recovery was observed in 91% of evaluable patients at three years, demonstrating that protracted B-cell aplasia is not a prerequisite for durable responses. Despite these advances, CAR T-cell therapy remains constrained by complex manufacturing logistics, high cost, and potentially severe toxicities, limiting its accessibility in routine clinical practice.

In parallel, bispecific antibodies (BsAbs) targeting CD20/CD3 — including glofitamab, epcoritamab, mosunetuzumab, and odronextamab — have rapidly advanced toward widespread clinical application, offering an off-the-shelf alternative with a manageable safety profile amenable to outpatient administration. The phase 3 SUNMO trial demonstrated significantly superior outcomes with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus R-GemOx in transplant-ineligible R/R LBCL patients, with a median PFS of 11.5 months versus 3.8 months (HR 0.41; P<0.0001) and overall response rates of 70% versus 40%. Supporting phase 1b/2 data for the Mosun-Pola combination showed a best overall response rate of 59.2% and a complete response rate of 45.9%, with a median duration of complete response that had not been reached at 23.9 months of follow-up. Two BsAbs have secured FDA approval for R/R LBCL, with additional approvals anticipated across earlier treatment lines, reflecting the accelerating clinical momentum of this drug class.

Beyond these headline modalities, the landscape has also been reshaped by the approval of antibody-drug conjugates and novel combination regimens. Polatuzumab vedotin combined with bendamustine and rituximab (Pola+BR) received US approval for R/R DLBCL, though real-world data from 69 patients — 84% of whom were refractory to prior therapy — revealed a response rate of 50% and a complete response rate of only 24%, with a median PFS of 2.0 months and median overall survival of 5.3 months, outcomes markedly inferior to those observed in clinical trials. In the frontline setting, PV-R-CHP demonstrated significantly higher 1-year PFS (89.3% vs. 70.9%; HR 0.30; p=0.013) and OS (92.5% vs. 80.0%; HR 0.28; p=0.041) compared to R-CHOP in untreated DLBCL, with particular benefit observed in non-GCB subtypes. Collectively, these data underscore a field in active evolution — with sequencing strategy, patient eligibility, and access equity emerging as critical determinants of optimal outcomes across an increasingly complex therapeutic armamentarium.

Roche's Mosun-Pola Combo: Reshaping R/R LBCL Care

The recent FDA acceptance of Roche's supplemental Biologics License Application for subcutaneous Lunsumio (mosunetuzumab) in combination with Polivy (polatuzumab vedotin) signals a significant potential shift in the treatment paradigm for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including DLBCL, after at least one prior line of systemic therapy. This development is particularly impactful for transplant-ineligible patients who currently face a poor prognosis and limited effective options.

The Phase III SUNMO study, which underpins this sBLA, demonstrated compelling efficacy, showing a 59% reduction in the risk of disease progression or death compared to the R-GemOx regimen. The median progression-free survival of 11.5 months for the mosunetuzumab/polatuzumab vedotin combination significantly outpaced R-GemOx's 3.8 months, alongside superior overall response and complete response rates. This data suggests a highly effective, chemotherapy-free approach that could offer durable responses. Furthermore, the subcutaneous administration of mosunetuzumab, combined with its fixed-duration nature, holds the promise of an 'off-the-shelf' and potentially outpatient treatment, enhancing patient convenience and access.

Scientifically, the combination is intriguing. Mosunetuzumab, a CD20xCD3 T-cell-engaging bispecific antibody, redirects T cells to eliminate malignant B cells, while polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, delivers a cytotoxic payload. Preclinical evidence indicates a synergistic effect, where polatuzumab vedotin may upregulate CD20 expression, thereby amplifying mosunetuzumab's T-cell redirection capabilities. This dual-targeting strategy represents a sophisticated advancement in immunotherapy.

However, several considerations remain. While the SUNMO trial reported infrequent Grade ≥2 cytokine release syndrome (CRS) events, bispecific antibodies are known to cause immune-related toxicities, necessitating careful monitoring in a broader patient population. The competitive landscape in R/R LBCL is also rapidly evolving, with numerous novel agents, including CAR-T therapies and other bispecific antibodies, vying for market share. The lengthy FDA review timeline, with a decision expected by February 2027, provides an extended window for competitors to advance their pipelines. Additionally, resistance mechanisms, such as the loss of CD20 expression, could emerge, potentially limiting long-term efficacy in some patients. Despite these challenges, the mosunetuzumab/polatuzumab vedotin combination represents a promising new option that could redefine the standard of care for a vulnerable patient population.